Prostvac is a poxviral-based vaccine designed to target prostate-specific antigen (PSA) in prostate cancer patients.
Recently, the potential toxicity and immunological impact of this immunotherapy were reviewed in the context of new clinical data. Our findings suggest that Prostvac is safe and elicits anticancer immune responses, both alone and in combinatorial approaches.
Written by:
Madan RA, Heery CR, Gulley JL. Are you the author?
Laboratory of Tumor Immunology and Biology; National Cancer Institute; National Institutes of Health; Bethesda, MD USA; Genitourinary Malignancies Branch; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
Reference: Oncoimmunology. 2014 Apr 29;3:e28611.
doi: 10.4161/onci.28611
PubMed Abstract
PMID: 25097802
UroToday.com Prostate Cancer Immunotherapy Section
